Sanofi reveals detailed timeframe for RSV candidate

Now that a new set of study data supports a possible treatment for RSV, Sanofi has laid out its plan for applying to regulatory authorities.
Photo: CHARLES PLATIAU/Reuters / X00217
Photo: CHARLES PLATIAU/Reuters / X00217

Over the course of the first six months of 2022, Sanofi expects to submit the first regulatory application for marketing authorization for a possible treatment of respiratory syncytial virus (RSV) in infants.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading